Ketamine Tablet and Bipolar Disorder

Bipolar disorder presents unique challenges and risks when considering ketamine therapy. On one hand, bipolar depression — which accounts for the majority of time spent symptomatic in bipolar disorder — is often treatment-resistant and associated with high suicide risk, creating genuine need for rapid-acting antidepressants. On the other hand, ketamine's mood-elevating properties raise concerns about triggering mania or destabilizing mood in bipolar patients. This article examines the evidence and clinical framework for navigating this complexity.

The Bipolar Depression Problem

Patients with bipolar disorder spend far more time in depressive episodes than manic or hypomanic episodes. Bipolar depression is:

• Often treatment-resistant to conventional antidepressants
• Associated with markedly elevated suicide risk
• Characterized by a concerning response to standard antidepressants — some studies suggest antidepressants may destabilize mood in bipolar patients, increasing cycling and risk of mixed states

The limited options for rapid-acting, effective treatment of bipolar depression create significant clinical need — and make ketamine's rapid antidepressant properties theoretically attractive.

Evidence for Ketamine in Bipolar Depression

IV Ketamine Studies

Several studies have specifically examined ketamine in bipolar depression:

Grunebaum et al. (2017): A randomized controlled crossover trial of IV ketamine vs. midazolam in 18 patients with bipolar I or II depression who were currently experiencing active suicidal ideation. Ketamine produced significant reductions in suicidal ideation and depressive symptoms within 24 hours. Notably, no patients experienced manic episodes during or after the infusion, though the follow-up period was brief.

Permoda-Osip et al. (2015): Examined IV ketamine in bipolar depression and reported response rates comparable to those in unipolar depression, with no manic switches observed during the acute treatment phase.

Murrough et al. (2013): While primarily examining unipolar TRD, this study included some bipolar II patients and found similar response rates without manic induction.

The Manic Switch Risk

The theoretical concern about ketamine inducing mania or hypomania is supported by several lines of evidence:

• Ketamine is a psychostimulant at subanesthetic doses — it increases dopamine release and activates reward circuits
• In genetically bipolar animals, ketamine produces manic-like behaviors at doses that are antidepressant in wild-type animals
• Individual case reports describe manic episodes following ketamine infusion in bipolar patients

However, the prospective clinical trials cited above — all conducted in bipolar patients on mood stabilizers — have not documented high rates of manic switch with single or short-course ketamine administration.

Key variable: Mood stabilizer coverage. Most patients in these trials were on lithium, valproate, or an atypical antipsychotic. Whether ketamine in bipolar patients without adequate mood stabilizer coverage carries higher mania risk is not well studied.

Ketamine Tablet-Specific Data

Dedicated studies of ketamine tablet specifically in bipolar disorder are very limited. Clinical experience and extrapolation from IV data inform most ketamine tablet use in this population. The lower bioavailability of ketamine tablet and the generally lower peak plasma levels compared to IV may translate to lower mania risk, but this has not been formally evaluated.

Risk Stratification by Bipolar Subtype

The risk-benefit calculus varies by bipolar subtype:

Bipolar I Disorder

Bipolar I — characterized by full manic episodes requiring hospitalization or causing marked functional impairment — carries the highest risk from ketamine. A full manic episode precipitated by ketamine could be life-threatening or require inpatient psychiatric hospitalization.

Ketamine for bipolar I depression is most appropriate when:

• Adequate mood stabilizer coverage is in place (lithium, valproate, or appropriate antipsychotic)
• The depressive episode is severe (significant suicidality, functional impairment)
• Conventional bipolar antidepressant treatments have failed or cannot be used
• Close monitoring for early signs of mood elevation is in place

Bipolar II Disorder

Bipolar II — characterized by hypomanic episodes rather than full mania — has a somewhat lower but still present risk of mood elevation with ketamine. Hypomania is often less dangerous than mania but can still cause significant harm through impulsive decisions and social disruption.

Some clinicians are more willing to use ketamine in carefully selected Bipolar II patients with severe, treatment-resistant depression.

Cyclothymia

Cyclothymia (mild mood cycling) represents the lowest risk within the bipolar spectrum, but caution remains appropriate.

Guidelines for Safer Use in Bipolar Disorder

If a clinician and patient determine that ketamine tablet is appropriate for bipolar depression, the following safeguards are generally recommended:

Prerequisite: Adequate Mood Stabilizer Coverage

Ketamine should not be used in bipolar patients who are not on adequate mood stabilizer therapy. Lithium, valproate (divalproex), lamotrigine, or an appropriate atypical antipsychotic (quetiapine, lurasidone, cariprazine) should be continued throughout ketamine therapy.

Lithium in particular has been hypothesized to reduce ketamine-induced mania risk based on its downstream effects on GSK-3β signaling pathways shared with ketamine's mechanism.

Conservative Dosing

Starting with lower oral doses than might be used in unipolar depression and titrating more cautiously reduces the acute mood-destabilizing risk.

Frequent Mood Monitoring

During ketamine therapy, bipolar patients should:

• Complete validated mood monitoring scales (e.g., MDQ, YMRS for mania; PHQ-9 for depression) at every session
• Keep a detailed mood diary
• Have clear instructions on what to report and when to contact their provider

Short Treatment Courses with Reassessment

Limiting ketamine to defined treatment courses (e.g., 4–6 weeks) rather than open-ended therapy, with formal reassessment of bipolar stability before extending treatment, is prudent.

Clear Mania Warning Signs

Patients and their support persons should be educated to recognize early signs of hypomania or mania:

• Decreased need for sleep (feeling rested on fewer hours)
• Elevated, expansive, or irritable mood beyond antidepressant effect
• Increased energy, talkativeness, or goal-directed activity
• Impulsive spending, sexual behavior, or other high-risk activities
• Racing thoughts

If any of these emerge, ketamine should be paused and the prescriber contacted urgently.

Monitoring Plan

A comprehensive monitoring plan for bipolar disorder patients on ketamine tablet includes:

• PHQ-9 for depression at each visit
• YMRS (Young Mania Rating Scale) or MDQ at each visit
• Blood pressure and vital signs
• Serum lithium levels (if on lithium) regularly — ketamine may affect fluid balance
• Quarterly comprehensive review of bipolar stability

The Bottom Line

Ketamine is not categorically contraindicated in bipolar disorder, but it carries meaningful risks that require careful management. With appropriate mood stabilizer coverage, conservative dosing, frequent monitoring, and clear safety planning, ketamine tablet can be a valuable option for the most refractory bipolar depression cases. This should only be pursued by clinicians with specific expertise in both bipolar disorder and ketamine therapy.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches